

Ministry of Health

COVID-19 Vaccination: Allergy Form

Version 2.0 February 11, 2021

This guidance provides basic information only. This document is not intended to provide or take the place of medical advice, diagnosis or treatment, or legal advice. In the event of any conflict between this guidance document and any orders or directives issued by the Minister of Health or the Chief Medical Officer of Health (CMOH), the order or directive prevails.

- Please check the Ministry of Health (MOH) [COVID-19](#) website regularly for updates to this document, mental health resources, and other information,
- Please check the [Directives, Memorandums and Other Resources](#) page regularly for the most up to date directives.

COVID-19 Vaccination in Specific Allergy Populations requires an assessment of vaccine safety and informed consent achieved through a discussion with a health care provider about the risks and benefits of vaccination in light of the risk of severe allergic reaction to COVID-19 vaccines in these specific populations. Documentation must be completed by an allergist-immunologist and provided to the vaccination clinic; in some cases, these individuals cannot be vaccinated in a general vaccine clinic. **Documentation** of the discussion with the allergist-immunologist must include a vaccination care plan, confirm that appropriate counselling on the safe administration of vaccine was provided, and include the date, the clinician's name, signature and contact information, as well as the individual's name and date of birth.

A Sample Allergy Documentation form can be found on Page 3 of this document.

The following populations must complete additional documentation prior to vaccination:

- 1) Individuals who have had a severe allergic reaction or anaphylaxis to a previous dose of a COVID-19 mRNA vaccine or to any of its components should not receive the mRNA COVID-19 vaccine in a general vaccine clinic. An urgent referral to an allergist/immunologist is recommended for these individuals. Such an assessment is required to assess the method for possible (re)administration of a COVID-19 vaccine.

- 2) Individuals who have had an allergic reaction within 4 hours of receiving a previous dose of an mRNA COVID-19 vaccine or any of components of the mRNA COVID-19 vaccine should not receive either mRNA COVID-19 vaccine unless they have been evaluated by an allergist-immunologist and it is determined that the person can safely receive the vaccine. The components include polyethylene glycol and, due to potential cross-reactivity, polysorbate.

See [Vaccination Recommendations for Special Populations](#) for additional information.

COVID-19 Vaccination: Sample Allergy Form

Version 2.0 February 2, 2021

Date (YYYY/MM/DD):			
<p>COVID-19 Vaccination in Special Allergy Populations requires an assessment of vaccine safety and informed consent achieved through a discussion with your health care provider about the risks and benefits of vaccination in light of the risk of severe allergic reaction to COVID-19 vaccines in these populations. An allergist-immunologist should complete this form together with the individual and attach a vaccination care plan. See Vaccination Recommendations for Special Populations for additional information.</p>			
Client Information			
Name:			
	Last		First
DOB:			OHIP/HCN:
	YYYY/MM/DD		
To be completed by the allergist-immunologist			
<p>The aforementioned individual and I have had a risk/benefit discussion regarding vaccination for COVID-19 . A vaccination care plan is attached.</p>			
Clinician Signature:			Patient Signature:
Clinician Name:			
Clinic Phone #:			Clinic Fax #: